Janux Therapeutics (JANX) Institutional Ownership

During the previous two years, 166 institutional investors and hedge funds held shares of Janux Therapeutics. The most heavily invested institutionals were RA Capital Management L.P. ($554.98M), FMR LLC ($464.19M), Janus Henderson Group PLC ($190.62M), Paradigm Biocapital Advisors LP ($188.25M), Adage Capital Partners GP L.L.C. ($163.93M), Vanguard Group Inc. ($114.38M), and BVF Inc. IL ($109.93M).Learn more on JANX's institutional investors.

75.39% of Janux Therapeutics stock is owned by institutional investors. Learn more on JANX's institutional investor holdings.

Of the 144 institutional investors that purchased Janux Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BVF Inc. IL ($2.64M), EcoR1 Capital LLC ($2.42M), FMR LLC ($2.18M), Janus Henderson Group PLC ($1.79M), RA Capital Management L.P. ($1.70M), Adage Capital Partners GP L.L.C. ($1.24M), and Paradigm Biocapital Advisors LP ($1.12M).

Institutional investors have bought a total of 27,385,245 shares in the last 24 months. This purchase volume represents approximately $1.10B in transactions.

Of the 43 institutional investors that sold Janux Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: BVF Inc. IL ($1.66M), Orbimed Advisors LLC ($500K), FMR LLC ($465.22K), Vestal Point Capital LP ($240K), Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. ($42.34K), Allspring Global Investments Holdings LLC ($40.26K), and State Street Corp ($40.06K).

Institutional investors have sold a total of 3,371,084 shares in the last 24 months. This volume of shares sold represents approximately $130.40M in transactions.